B7-33
Also known as: Relaxin-2 mimetic, Mimético de Relaxina-2
Overview
Single-chain mimetic peptide of human relaxin-2, designed to selectively activate the RXFP1 receptor. Unlike native relaxin-2 which has a two-chain structure, B7-33 consists of a single chain derived from the B-chain of relaxin, simplifying production while maintaining anti-fibrotic and vasodilatory biological activity.
Single-chain peptide — relaxin-2 mimetic with simplified structure
Half-life
~1-2 hours
Administration Route
Subcutaneous
Category
Specialized Research
Mechanism of Action
- Selective agonism of the RXFP1 receptor (relaxin family peptide receptor 1)
- Anti-fibrotic effect via inhibition of collagen deposition and extracellular matrix remodeling
- Vasodilation mediated by nitric oxide (NO) and endothelin
- Reduction of tissue inflammation and fibrosis in target organs
- Modulation of TGF-β signaling and pro-fibrotic pathways
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 100-500 mcg per injection (subcutaneous) |
| Frequency | Once daily |
| Timing | Per clinical guidance |
| Duration | 4-8 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild hypotension
- Headache
- Facial flushing
Presentations & Preparation
Vials of B7-33 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 1-2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved — never shake
- Wait for complete dissolution before use
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Limited stability after reconstitution
Scientific Studies
Published studies on B7-33.
B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin)
Marshall SA, O'Sullivan K, Ng HH, Bathgate RAD, Parry LJ, Hossain MA, Leo CH
B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice
Devarakonda T, Mauro AG, Guzman G, Hovsepian S, Cain C, Das A, Praveen P, Hossain MA, Salloum FN
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily